{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:27:48Z","timestamp":1787153268762,"version":"build-2736575974"},"reference-count":52,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"\n Importance<\/jats:title>\n Comparative efficacy and tolerability of topical therapies for rosacea remain incompletely characterized, particularly for novel agents such as encapsulated benzoyl peroxide.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare the efficacy and tolerability of topical treatments for moderate to severe rosacea through a systematic review and network meta-analysis of randomized clinical trials (RCTs).<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n CENTRAL (Cochrane Central Register of Controlled Trials), MEDLINE via Ovid, Web of Science, and Embase databases were searched from inception through August 6, 2025, and supplemented by manual screening of references.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n RCTs published in English that included adults with moderate to severe rosacea and assessed topical therapies for rosacea were included.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n Two reviewers independently extracted data and assessed risk of bias using the Cochrane Risk of Bias tool, version 2.0. Data were synthesized using random-effects network meta-analyses. Treatment rankings were estimated using SUCRA (surface under the cumulative ranking) values. Certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation framework.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Prespecified primary outcomes were mean change in absolute lesion count, Investigator Global Assessment (IGA) success, and discontinuation due to adverse events or effects. Secondary outcomes included patient-reported measures and clinician-assessed erythema.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 2858 records screened, 32 RCTs met inclusion criteria, comprising a total of 11\u202f399 adults treated with 10 topical interventions. Most studies had a 8- to 16-week follow-up period. Compared with metronidazole, ivermectin and encapsulated benzoyl peroxide demonstrated greater reductions in lesion count (mean difference [MD], 4.17; 95% CI, 1.85-6.48; and MD, 4.14; 95% CI, 0.62-7.66, respectively) and higher likelihood of IGA success (MD, 10.31; 95% CI, 2.85 to 17.77; and MD, 15.51; 95% CI, 2.35-28.68, respectively). Frequency of discontinuation due to adverse events were similar between treatments, although discontinuation was more frequent with encapsulated benzoyl peroxide than metronidazole (MD, 8.33; 95% CI, 0.45-16.22). Limited data precluded robust quantitative synthesis of patient-reported outcomes and erythema outcomes.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this systematic review and network meta-analysis, topical ivermectin and encapsulated benzoyl peroxide were more efficacious than metronidazole for rosacea, although encapsulated benzoyl peroxide was also associated with higher discontinuation due to adverse events. Future trials should evaluate long-term efficacy, tolerability, and standardized patient-reported outcomes.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2026.2062","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:40:04Z","timestamp":1782920404000},"page":"787","source":"Crossref","is-referenced-by-count":0,"title":["Topical Preparations for Moderate to Severe Rosacea Treatment"],"prefix":"10.1001","volume":"162","author":[{"given":"Anissa Valentina","family":"Amstutz","sequence":"first","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abizairie","family":"S\u00e1nchez-Feliciano","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza","family":"Dewey","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Biba","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Salloum","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Associate Editor, JAMA Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"doi260024r1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/bjd.17590","article-title":"Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments.","volume":"181","author":"van Zuuren","year":"2019","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi260024r2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003262.pub5","article-title":"Interventions for rosacea.","volume":"2015","author":"van Zuuren","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"doi260024r3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1517825","article-title":"Efficacy and safety of topical minocycline preparations for papulopustular rosacea: a systematic review and meta-analysis.","volume":"12","author":"Alamri","year":"2025","journal-title":"Front Med (Lausanne)"},{"issue":"22","key":"doi260024r4","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1001\/jama.2015.15287","article-title":"Interventions for rosacea.","volume":"314","author":"van Zuuren","year":"2015","journal-title":"JAMA"},{"issue":"3","key":"doi260024r5","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.12788\/cutis.0067","article-title":"Active comparator trial designs used to promote development of innovative new medications.","volume":"106","author":"Barbieri","year":"2020","journal-title":"Cutis"},{"issue":"5","key":"doi260024r6","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1001\/jamadermatol.2021.0356","article-title":"Use of active comparator trials for topical medications in dermatology.","volume":"157","author":"Miller","year":"2021","journal-title":"JAMA Dermatol"},{"key":"doi260024r7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jdin.2023.12.010","article-title":"The efficacy and safety of minocycline, metronidazole, ivermectin, and azelaic acid in moderate-to-severe papulopustular rosacea: A systematic review and network meta-analysis.","volume":"20","author":"Shaheen","year":"2024","journal-title":"JAAD Int"},{"issue":"8","key":"doi260024r8","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.ad.2024.12.026","article-title":"Efficacy of widely used topical drugs for rosacea: a systematic review and meta-analysis.","volume":"116","author":"Gao","year":"2025","journal-title":"Actas Dermosifiliogr"},{"key":"doi260024r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.parepi.2025.e00461","article-title":"Efficacy of topical ivermectin in controlling human Demodex infestation: evidence from systematic review and meta-analysis.","volume":"31","author":"Paichitrojjana","year":"2025","journal-title":"Parasite Epidemiol Control"},{"issue":"12","key":"doi260024r10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2025-109057","article-title":"Topical medications for moderate-to-severe rosacea: protocol for a living systematic review and network meta-analysis.","volume":"15","author":"Amstutz","year":"2025","journal-title":"BMJ Open"},{"issue":"18","key":"doi260024r13","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMcp1506630","article-title":"Rosacea.","volume":"377","author":"van Zuuren","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"doi260024r14","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.jaad.2020.01.043","article-title":"Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: results of 2 phase 3, randomized, clinical trials.","volume":"82","author":"Gold","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi260024r15","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/bjd.18857","article-title":"A multicentre, randomized, double-masked, parallel group, vehicle-controlled phase IIb study to evaluate the safety and efficacy of 1% and 3% topical minocycline gel in patients with papulopustular rosacea.","volume":"183","author":"Webster","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi260024r17","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40265-024-02003-w","article-title":"Microencapsulated benzoyl peroxide for rosacea in context: a review of the current treatment landscape.","volume":"84","author":"Desai","year":"2024","journal-title":"Drugs"},{"issue":"3","key":"doi260024r19","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1365-4632.2004.02130.x","article-title":"Adapalene vs. metronidazole gel for the treatment of rosacea.","volume":"44","author":"Altinyazar","year":"2005","journal-title":"Int J Dermatol"},{"issue":"3","key":"doi260024r20","first-page":"290","article-title":"Pivotal trial of the efficacy and safety of oxymetazoline cream 1.0% for the treatment of persistent facial erythema associated with rosacea: findings from the second REVEAL trial.","volume":"17","author":"Baumann","year":"2018","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"doi260024r21","first-page":"34","article-title":"Efficacy and safety of microencapsulated benzoyl peroxide cream, 5%, in rosacea: results from two phase III, randomized, vehicle-controlled trials.","volume":"16","author":"Bhatia","year":"2023","journal-title":"J Clin Aesthet Dermatol"},{"issue":"6","key":"doi260024r22","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1080\/000155599750009906","article-title":"Double-blind comparison of azelaic acid 20% cream and its vehicle in treatment of papulo-pustular rosacea.","volume":"79","author":"Bjerke","year":"1999","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"doi260024r23","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1365-4632.2004.02283.x","article-title":"Double-blind, randomized, vehicle-controlled clinical trial of once-daily benzoyl peroxide\/clindamycin topical gel in the treatment of patients with moderate to severe rosacea.","volume":"43","author":"Breneman","year":"2004","journal-title":"Int J Dermatol"},{"issue":"1","key":"doi260024r24","first-page":"44","article-title":"A double-blind, multicenter clinical trial comparing efficacy of once-daily metronidazole 1 percent cream to vehicle in patients with rosacea.","volume":"61","author":"Breneman","year":"1998","journal-title":"Cutis"},{"issue":"1","key":"doi260024r25","first-page":"54","article-title":"A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea.","volume":"96","author":"Draelos","year":"2015","journal-title":"Cutis"},{"issue":"6","key":"doi260024r26","first-page":"306","article-title":"Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double-blind, vehicle-controlled study.","volume":"92","author":"Draelos","year":"2013","journal-title":"Cutis"},{"issue":"3","key":"doi260024r27","first-page":"308","article-title":"Phase 2 randomized, dose-ranging study of oxymetazoline cream for treatment of persistent facial erythema associated with rosacea.","volume":"17","author":"DuBois","year":"2018","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"doi260024r28","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1001\/archderm.139.11.1444","article-title":"A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial.","volume":"139","author":"Elewski","year":"2003","journal-title":"Arch Dermatol"},{"issue":"3","key":"doi260024r29","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1365-2133.2011.10716.x","article-title":"Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.","volume":"166","author":"Fowler","year":"2012","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi260024r30","first-page":"650","article-title":"Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies.","volume":"12","author":"Fowler","year":"2013","journal-title":"J Drugs Dermatol"},{"issue":"12","key":"doi260024r31","first-page":"1410","article-title":"Clindamycin phosphate 1.2% and tretinoin 0.025% gel for rosacea: summary of a placebo-controlled, double-blind trial.","volume":"11","author":"Freeman","year":"2012","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"doi260024r32","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S0190-9622(98)70337-8","article-title":"The efficacy of metronidazole 1% cream once daily compared with metronidazole 1% cream twice daily and their vehicles in rosacea: a double-blind clinical trial.","volume":"39","author":"Jorizzo","year":"1998","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"doi260024r33","first-page":"909","article-title":"Treatment of rosacea with concomitant use of topical ivermectin 1% cream and brimonidine 0.33% gel: a randomized, vehicle-controlled study.","volume":"16","author":"Gold","year":"2017","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"doi260024r34","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1159\/000065849","article-title":"Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea: a randomized double-blind placebo-controlled study.","volume":"205","author":"Ko\u00e7ak","year":"2002","journal-title":"Dermatology"},{"issue":"1","key":"doi260024r35","first-page":"97","article-title":"Pivotal trial of the efficacy and safety of oxymetazoline cream 1.0% for the treatment of persistent facial erythema associated with rosacea: findings from the first REVEAL trial.","volume":"17","author":"Kircik","year":"2018","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"doi260024r36","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/j.1365-2230.2009.03427.x","article-title":"A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: a randomized open-label clinical trial.","volume":"35","author":"Koca","year":"2010","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"doi260024r37","first-page":"685","article-title":"Randomized, phase 2, dose-ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel.","volume":"13","author":"Leyden","year":"2014","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"doi260024r38","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/1346-8138.16254","article-title":"Metronidazole gel (0.75%) in Japanese patients with rosacea: a randomized, vehicle-controlled, phase 3 study.","volume":"49","author":"Miyachi","year":"2022","journal-title":"J Dermatol"},{"issue":"3","key":"doi260024r39","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s40257-017-0339-0","article-title":"A phase II, randomized, double-blind clinical study evaluating the safety, tolerability, and efficacy of a topical minocycline foam, FMX103, for the treatment of facial papulopustular rosacea.","volume":"19","author":"Mrowietz","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"doi260024r40","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1365-2133.1983.tb03972.x","article-title":"Treatment of rosacea with i% metronidazole cream: a double-blind study.","volume":"108","author":"Nielsen","year":"1983","journal-title":"Br J Dermatol"},{"issue":"8","key":"doi260024r41","first-page":"19","article-title":"Effect of topical microencapsulated benzoyl peroxide on the skin microbiome in rosacea: a randomized, double-blind, crossover, vehicle-controlled clinical trial.","volume":"17","author":"Nong","year":"2024","journal-title":"J Clin Aesthet Dermatol"},{"issue":"3","key":"doi260024r42","first-page":"187","article-title":"Investigator-reported efficacy of azelaic acid foam 15% in patients with papulopustular rosacea: secondary efficacy outcomes from a randomized, controlled, double-blind, phase 3 trial.","volume":"98","author":"Solomon","year":"2016","journal-title":"Cutis"},{"issue":"11","key":"doi260024r43","first-page":"1380","article-title":"Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials.","volume":"13","author":"Stein Gold","year":"2014","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"doi260024r44","first-page":"316","article-title":"Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies.","volume":"13","author":"Stein","year":"2014","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"doi260024r45","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1111\/bjd.13408","article-title":"Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial.","volume":"172","author":"Taieb","year":"2015","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi260024r46","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10227-001-0144-4","article-title":"Randomized placebo-controlled trial of metronidazole 1% cream with sunscreen SPF 15 in treatment of rosacea.","volume":"6","author":"Tan","year":"2002","journal-title":"J Cutan Med Surg"},{"issue":"6","key":"doi260024r47","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1067\/mjd.2003.308","article-title":"Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies.","volume":"48","author":"Thiboutot","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi260024r48","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/j.1365-2133.2006.07669.x","article-title":"Pimecrolimus cream 1% for papulopustular rosacea: a randomized vehicle-controlled double-blind trial.","volume":"156","author":"Weissenbacher","year":"2007","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi260024r49","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1001\/jamadermatol.2024.0636","article-title":"Rosacea core domain set for clinical trials and practice: a consensus statement.","volume":"160","author":"Dirr","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"5","key":"doi260024r50","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/jdv.18918","article-title":"Quality of life measurement in rosacea. Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa.","volume":"37","author":"Chernyshov","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"doi260024r51","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1001\/jamadermatol.2022.3911","article-title":"Use of patient-reported outcomes in acne vulgaris and rosacea clinical trials from 2011 to 2021: a systematic review.","volume":"158","author":"Ly","year":"2022","journal-title":"JAMA Dermatol"},{"key":"doi260024r52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2024.111537","article-title":"Network meta-analysis: a powerful tool for clinicians, decision-makers, and methodologists.","volume":"176","author":"Florez","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"doi260024r11","unstructured":"DailyMed. Metronidazole gel. Accessed December 22, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=4a233572-2471-4e99-a45e-2de978abcf16"},{"key":"doi260024r12","unstructured":"DailyMed. Metronidazole lotion. Accessed December 22, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=fce3e59e-8e08-47f1-947f-5a6d141ba1b2"},{"key":"doi260024r16","unstructured":"DailyMed. FINACEA FOAM-azelaic acid aerosol, foam. Accessed December 22, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=9fabd24e-4c3b-49a0-aa5f-c8d75ae67572"},{"key":"doi260024r18","unstructured":"DailyMed. EPSOLAY, benzoyl peroxide cream. Accessed December 22, 2025. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=507e2cd7-6bcf-4606-bc62-694d64537701"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2851180\/jamadermatology_amstutz_2026_oi_260024_1786734777.53222.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:00:26Z","timestamp":1787151626000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2851180"}},"subtitle":["A Systematic Review and Network Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.2062","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}